NCT00436917View on ClinicalTrials.gov

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

May 9, 2016

Conditions
Breast CancerOsteoporosis
Interventions
DRUG

zoledronic acid

zoledronic acid

PROCEDURE

Letrozole as adjuvant therapy

standard care

Trial Locations (2)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00436917 - Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer | Biotech Hunter | Biotech Hunter